Drug

Triclosan

In clinical development

ClassBacterial enoyl-[acyl-carrier-protein] reductase inhibitorEmerging researchLate-stage development

Also known as Triclosán, 2,4,4'-Trichloro-2'-hydroxydiphenyl ether, 5-Chloro-2-(2,4-dichloro-phenoxy)-phenol, Triclosanum.

RxNorm10795 ChEMBLCHEMBL849 ATCD08AE04 ATCD09AA06UNII4NM5039Y5X

Research papers

fabI

Primary target

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Effects of triclosan on cytokine production by human immune cells in vitro.

Research2025-06-17Environment international

Triclosan as Adjunctive Therapy in the Plaque Control in Children From Generalized Aggressive Periodontitis Families. A Controlled and Randomized Clinical Trial.

Clinical trial2016-12-20Completed · ClinicalTrials.gov

Effectiveness of Triclosan Coated VICRYL\MONOCRYL Sutures in Preventing Leg Wound Infection Compared to POLYSORB\ BIOSYN Sutures in Patients After Coronary Bypass Surgery- a Randomized Controlled Trial

Clinical trial2013-10-01Primary completion · ClinicalTrials.gov

Clinical Study to Evaluate the Treatment of Gingivitis of Two Toothpastes

Clinical trial2010-12-28Results posted · ClinicalTrials.gov

Periodontal Disease and Cardiovascular Disease

Clinical trial2009-12-01Primary completion · ClinicalTrials.gov

Training and Calibration of Dental Examiners

Clinical trial2007-12-01Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Triclosan

Aliases & brands

Triclosán2,4,4'-Trichloro-2'-hydroxydiphenyl ether5-Chloro-2-(2,4-dichloro-phenoxy)-phenolTriclosanum

RxNorm CUI

10795

ChEMBL ID

CHEMBL849

ATC codes

D08AE04D09AA06

UNII

4NM5039Y5X

Primary mechanism

Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Enoyl-[acyl-carrier-protein] reductase [NADH] FabI

fabI · P0AEK4

INHIBITORBacterial enoyl-[acyl-carrier-protein] reductase inhibitor

Clinical trials

5 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2016

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 5

Phase 33Phase 42

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Triclosan as Adjunctive Therapy in the Plaque Control in Children From Generalized Aggressive Periodontitis Families. A Controlled and Randomized Clinical Trial.

CompletedPH IVUniversity of Campinas, Braziln=402016

Unknown statusPH IVRambam Health Care Campusn=4102013

Periodontal Disease and Cardiovascular Disease

Unknown statusPH IIIColgate Palmoliven=4382009

Clinical Study to Evaluate the Treatment of Gingivitis of Two Toothpastes

CompletedPH IIIColgate Palmoliven=442008

Training and Calibration of Dental Examiners

CompletedPH IIIColgate Palmoliven=182007

Recent completions

Trials that read out recently, adding to the completed evidence base.

Triclosan as Adjunctive Therapy in the Plaque Control in Children From Generalized Aggressive Periodontitis Families. A Controlled and Randomized Clinical Trial.

CompletedPH IVUniversity of Campinas, Braziln=402016

Clinical Study to Evaluate the Treatment of Gingivitis of Two Toothpastes

CompletedPH IIIColgate Palmoliven=442008

Training and Calibration of Dental Examiners

CompletedPH IIIColgate Palmoliven=182007

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Effects of triclosan on cytokine production by human immune cells in vitro.

Environment international · 2025 · 4 cites